{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T04:07:33Z","timestamp":1746245253318,"version":"3.40.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Platform Special Fund for Scientific Research of Xiangyang No.1 People\u2019s Hospital","award":["XYY2022P05"],"award-info":[{"award-number":["XYY2022P05"]}]},{"name":"Innovative Research Program of Xiangyang No.1 People's Hospital","award":["XYY2023SD06 and XYY2023QB07"],"award-info":[{"award-number":["XYY2023SD06 and XYY2023QB07"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s10637-025-01521-y","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T06:55:50Z","timestamp":1743317750000},"page":"425-432","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare exon 18 G719A and exon 21 L833V compound EGFR mutations show favorable response to Third-Generation TKI Furmonertinib: A case report and literature review"],"prefix":"10.1007","volume":"43","author":[{"family":"Yuejian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jijun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"1521_CR1","doi-asserted-by":"publisher","first-page":"103194","DOI":"10.1016\/j.critrevonc.2020.103194","volume":"157","author":"EN Imyanitov","year":"2021","unstructured":"Imyanitov EN, Iyevleva AG, Levchenko EV (2021) Molecular testing and targeted therapy for non-small cell lung cancer: current status and perspectives, (in eng). Crit Rev Oncol Hematol 157:103194","journal-title":"Crit Rev Oncol Hematol"},{"key":"1521_CR2","doi-asserted-by":"crossref","unstructured":"Chen P, Liu Y, Wen Y, Zhou C (2022) Non-small cell lung cancer in China, (in eng). Cancer Commun (Lond) 42(10):937\u2013970","DOI":"10.1002\/cac2.12359"},{"key":"1521_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.lungcan.2017.08.021","volume":"113","author":"B Han","year":"2017","unstructured":"Han B et al (2017) EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: the IGNITE study, (in eng). Lung Cancer (Amsterdam Netherlands) 113:37\u201344","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"1521_CR4","doi-asserted-by":"crossref","unstructured":"Yang JCH et al (2015) Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6, (in eng). Lancet Oncol 16(7):830\u2013838","DOI":"10.1016\/S1470-2045(15)00026-1"},{"issue":"3","key":"1521_CR5","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s10147-006-0583-4","volume":"11","author":"T Mitsudomi","year":"2006","unstructured":"Mitsudomi T, Kosaka T, Yatabe Y (2006) Biological and clinical implications of EGFR mutations in lung cancer, (in eng). Int J Clin Oncol 11(3):190\u2013198","journal-title":"Int J Clin Oncol"},{"key":"1521_CR6","doi-asserted-by":"crossref","unstructured":"Attili I, Passaro A, Pisapia P, Malapelle U, de Marinis F (Jan 9 2022) Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence, (in eng). Current oncology (Toronto, Ont.) 29(1):255\u2013266","DOI":"10.3390\/curroncol29010024"},{"key":"1521_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.lungcan.2019.02.001","volume":"130","author":"H Li","year":"2019","unstructured":"Li H et al (2019) Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy, (in eng). Lung Cancer (Amsterdam Netherlands) 130:42\u201349","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"1521_CR8","doi-asserted-by":"crossref","unstructured":"Dodero A et al (May 1 2022) Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome, (in eng). Haematologica 107(5):1153\u20131162","DOI":"10.3324\/haematol.2021.278638"},{"key":"1521_CR9","doi-asserted-by":"crossref","unstructured":"Passaro A et al (2019) Activity of EGFR TKIs in Caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations, (in eng). Clin Lung Cancer 20(2):e186-e194","DOI":"10.1016\/j.cllc.2018.11.005"},{"key":"1521_CR10","doi-asserted-by":"crossref","unstructured":"Moran T et al (2020) Clinical activity of Afatinib in patients with Non-Small-Cell lung Cancer harboring uncommon EGFR mutations: A Spanish retrospective multicenter study, (in eng). Clin Lung Cancer 21(5)","DOI":"10.1016\/j.cllc.2020.04.011"},{"key":"1521_CR11","doi-asserted-by":"crossref","unstructured":"Shi Y et al (Nov 2022) Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study, (in eng). The Lancet. Respiratory medicine 10(11):1019\u20131028","DOI":"10.1016\/S2213-2600(22)00168-0"},{"key":"1521_CR12","doi-asserted-by":"crossref","unstructured":"Shi Y et al (2021 Aug) Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study, (in eng). The Lancet. Respiratory medicine 9(8):829\u2013839","DOI":"10.1016\/S2213-2600(20)30455-0"},{"key":"1521_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.humpath.2020.07.007","volume":"103","author":"T Hayashi","year":"2020","unstructured":"Hayashi T et al (2020) Clinicopathological characteristics of lung adenocarcinoma with compound EGFR mutations, (in eng). Hum Pathol 103:42\u201351","journal-title":"Hum Pathol"},{"key":"1521_CR14","doi-asserted-by":"publisher","first-page":"602726","DOI":"10.3389\/pore.2021.602726","volume":"27","author":"L Mao","year":"2021","unstructured":"Mao L et al (2021) Mutation spectrum of EGFR from 21,324 Chinese patients with Non-Small cell lung Cancer (NSCLC) successfully tested by multiple methods in a CAP-Accredited laboratory, (in eng). Pathol Oncol Res 27:602726","journal-title":"Pathol Oncol Res"},{"key":"1521_CR15","doi-asserted-by":"publisher","first-page":"6104","DOI":"10.1038\/srep06104","volume":"4","author":"L Peng","year":"2014","unstructured":"Peng L, Song Z-G, Jiao S-C (2014) Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations, (in eng). Sci Rep 4:6104","journal-title":"Sci Rep"},{"key":"1521_CR16","doi-asserted-by":"crossref","unstructured":"Wu S-G et al (2008) Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern, (in eng). Oncologist 13(12):1276\u20131284","DOI":"10.1634\/theoncologist.2008-0093"},{"key":"1521_CR17","doi-asserted-by":"crossref","unstructured":"Zhang B et al (2018) Complex epidermal growth factor receptor mutations and their responses to tyrosine kinase inhibitors in previously untreated advanced lung adenocarcinomas, (in eng). Cancer 124(11):2399\u20132406","DOI":"10.1002\/cncr.31329"},{"issue":"5","key":"1521_CR18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jtho.2019.12.126","volume":"15","author":"JC-H Yang","year":"2020","unstructured":"Yang JC-H et al (2020) Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: A database of 693 cases, (in eng). J Thorac Oncol 15(5):803\u2013815","journal-title":"J Thorac Oncol"},{"key":"1521_CR19","doi-asserted-by":"publisher","first-page":"175883592094615","DOI":"10.1177\/1758835920946156","volume":"12","author":"S-G Wu","year":"2020","unstructured":"Wu S-G, Yu C-J, Yang JC-H, Shih J-Y (2020) The effectiveness of Afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation, (in eng). Ther Adv Med Oncol 12:1758835920946156","journal-title":"Ther Adv Med Oncol"},{"key":"1521_CR20","doi-asserted-by":"publisher","first-page":"646577","DOI":"10.3389\/fonc.2021.646577","volume":"11","author":"J Tan","year":"2021","unstructured":"Tan J et al (2021) The predictive values of advanced Non-Small cell lung Cancer patients harboring uncommon EGFR mutations-The mutation patterns, use of different generations of EGFR-TKIs, and concurrent genetic alterations, (in eng). Front Oncol 11:646577","journal-title":"Front Oncol"},{"key":"1521_CR21","doi-asserted-by":"crossref","unstructured":"Wang C, Zhao K, Hu S, Dong W, Gong Y, Xie C (2023) Clinical outcomes of Afatinib versus osimertinib in patients with Non-Small cell lung Cancer with uncommon EGFR mutations: A pooled analysis, (in eng). Oncologist 28(6):e397-e405.","DOI":"10.1093\/oncolo\/oyad111"},{"key":"1521_CR22","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcancer.2019.09.015","volume":"61","author":"PT Harrison","year":"2020","unstructured":"Harrison PT, Vyse S, Huang PH (2020) Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer, (in eng). Semin Cancer Biol 61:167\u2013179","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"1521_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.19.00931","volume":"38","author":"JH Cho","year":"2020","unstructured":"Cho JH et al (2020) Osimertinib for patients with Non-Small-Cell lung Cancer harboring uncommon EGFR mutations: A multicenter, Open-Label, phase II trial (KCSG-LU15-09), (in eng). J Clin Oncol 38(5):488\u2013495","journal-title":"J Clin Oncol"},{"issue":"4","key":"1521_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","volume":"22","author":"GJ Riely","year":"2024","unstructured":"Riely GJ et al (2024) Non-Small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology, (in eng). J Natl Compr Canc Netw 22(4):249\u2013274","journal-title":"J Natl Compr Canc Netw"},{"key":"1521_CR25","doi-asserted-by":"publisher","first-page":"10689","DOI":"10.2147\/OTT.S260157","volume":"13","author":"X Long","year":"2020","unstructured":"Long X, Qin T, Lin J (2020) Great efficacy of Afatinib in a patient with lung adenocarcinoma harboring EGFR L833V\/H835L mutations: A case report, (in eng). Onco Targets Ther 13:10689\u201310692","journal-title":"Onco Targets Ther"},{"key":"1521_CR26","doi-asserted-by":"crossref","unstructured":"Yang X, Yao Y, Zhu Q (2022) A L833V\/H835L EGFR variant lung adenocarcinoma with skin metastasis: A case report and literature review, (in eng). Heliyon 8(12):e12080","DOI":"10.1016\/j.heliyon.2022.e12080"},{"key":"1521_CR27","doi-asserted-by":"publisher","first-page":"4739","DOI":"10.2147\/OTT.S167346","volume":"11","author":"B-D Qin","year":"2018","unstructured":"Qin B-D et al (2018) The effectiveness of Afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W\/H835L\/L833V): a case report and literature review, (in eng). Onco Targets Ther 11:4739\u20134745","journal-title":"Onco Targets Ther"},{"issue":"16","key":"1521_CR28","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1200\/JCO.2010.33.5802","volume":"29","author":"T-Y Yang","year":"2011","unstructured":"Yang T-Y, Tsai C-R, Chen K-C, Hsu K-H, Lee H-M, Chang G-C (2011) Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene, (in eng). J Clin Oncol 29(16):e468\u2013e469","journal-title":"J Clin Oncol"},{"issue":"3","key":"1521_CR29","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.cllc.2012.11.003","volume":"14","author":"Y Zhuang","year":"2013","unstructured":"Zhuang Y et al (2013) A sequential method of epidermal growth factor receptor mutation detection reduces false negatives: a new case with doublet mutations of L833V and H835L in China, (in eng). Clin Lung Cancer 14(3):295\u2013300","journal-title":"Clin Lung Cancer"},{"key":"1521_CR30","doi-asserted-by":"crossref","unstructured":"Frega S, Conte P, Fassan M, Polo V, Pasello G (2016) A triple rare E709K and L833V\/H835L EGFR mutation responsive to an irreversible Pan-HER inhibitor: A case report of lung adenocarcinoma treated with Afatinib, (in eng). J Thorac Oncol 11(5):e63-e64.","DOI":"10.1016\/j.jtho.2016.01.023"},{"issue":"8","key":"1521_CR31","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/15384047.2019.1595280","volume":"20","author":"M Li","year":"2019","unstructured":"Li M et al (2019) The in cis compound EGFR mutations in Chinese advanced non-small cell lung cancer patients, (in eng). Cancer Biol Ther 20(8):1097\u20131104","journal-title":"Cancer Biol Ther"},{"issue":"21","key":"1521_CR32","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1111\/1759-7714.14156","volume":"12","author":"T Li","year":"2021","unstructured":"Li T et al (2021) Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations, (in eng). Thorac Cancer 12(21):2924\u20132932","journal-title":"Thorac Cancer"},{"issue":"8","key":"1521_CR33","first-page":"939","volume":"34","author":"Z Luo","year":"2023","unstructured":"Luo Z, Luo C, Zhou R, Xiao Y, Wang T (2023) Complete response to first-line osimertinib monotherapy in a complex epidermal growth factor receptor mutant (L833V \/ H835L) lung adenocarcinoma patient: a case report, (in eng). Anticancer Drugs 34(8):939\u2013941","journal-title":"Anticancer Drugs"},{"issue":"4","key":"1521_CR34","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.cllc.2023.01.010","volume":"24","author":"JT Smith","year":"2023","unstructured":"Smith JT, Puri S, Akerley W (2023) Brief report: EGFR L833V\/H835L Duplex-Mutated NSCLC with leptomeningeal carcinomatosis responsive to osimertinib, (in eng). Clin Lung Cancer 24(4):360\u2013361","journal-title":"Clin Lung Cancer"},{"key":"1521_CR35","unstructured":"\u6768\u6893 \u59dc\u4f1f (2023) \u5f20\u8a00\u6b66, \u535c\u4e3d\u4f73, and \u6c5f\u6d01\u7f8e, \u57c3\u514b\u66ff\u5c3c\u8054\u5408\u5316\u7597\u6cbb\u7597\u80ba\u764cEGFR\u57fa\u56e0L833V\u548cH835L\u7f55\u89c1\u590d\u5408\u7a81\u53d81\u4f8b %J \u80bf\u7624\u836f\u5b66 13(03):385\u2013388"},{"issue":"33","key":"1521_CR36","doi-asserted-by":"publisher","first-page":"e30080","DOI":"10.1097\/MD.0000000000030080","volume":"101","author":"B Zhou","year":"2022","unstructured":"Zhou B, Wang Y, Liao H, Li B (2022) Effective treatment with Icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A\/L833V: A case report, (in eng). Med (Baltim) 101(33):e30080","journal-title":"Med (Baltim)"},{"key":"1521_CR37","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.lungcan.2019.10.030","volume":"139","author":"AC Sousa","year":"2020","unstructured":"Sousa AC et al (2020) Detection of rare and novel EGFR mutations in NSCLC patients: implications for treatment-decision, (in eng). Lung Cancer (Amsterdam Netherlands) 139:35\u201340","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"key":"1521_CR38","doi-asserted-by":"publisher","first-page":"1159308","DOI":"10.3389\/fonc.2023.1159308","volume":"13","author":"H Pan","year":"2023","unstructured":"Pan H, Zhang L, Meng F, Guan S, Zhong D (2023) EGFR p.V774M\/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report, (in eng). Front Oncol 13:1159308","journal-title":"Front Oncol"},{"issue":"10","key":"1521_CR39","first-page":"795","volume":"26","author":"Y Miao","year":"2023","unstructured":"Miao Y et al (2023) [A rare case of lung adenocarcinoma with EGFR L833V\/H835L Co-mutation and literature review], (in chi). Zhongguo Fei Ai Za Zhi 26(10):795\u2013800","journal-title":"Zhongguo Fei Ai Za Zhi"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01521-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01521-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T13:41:15Z","timestamp":1746193275000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01521-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1521"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01521-y","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics and Scientific Committee of Hubei University of Medicine with approval number 2022PR-H002. Written informed consent was obtained from the individual for the publication of any potentially identifiable images included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}